Harvey S. Hecht
Research Subjects
Harvey S. Hecht has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Vladimir Jelnin
4 shared publicationsJagat Narula
University of Texas Health, Houston, Texas, USA
3 shared publicationsS.Mitchell Harman
Kronos Longevity Research Institute, Phoenix, Arizona, USA
3 shared publicationsDaniel S. Berman
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
2 shared publicationsGary Roubin
2 shared publicationsGary S. Roubin
Lenox Hill Heart and Vascular Institute, New York, New York
2 shared publications
Latest Publications
- 16 August 2023
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 16 (12) , 1565-1566
The Prerequisites for Cardiac Imaging Tests
- 16 August 2023
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 16 (12) , 1565-1566
The Prerequisites for Cardiac Imaging Tests
- Top Cited Papers
- 1 March 2017
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 11 (2) , 157-168
Clinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus statement from the Society of Cardiovascular Computed Tomography
- 1 March 2017
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 11 (2) , 157-168
Top Cited PapersClinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus statement from the Society of Cardiovascular Computed Tomography
- 1 December 2015
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 8 (12) , 1401-1403
In Sickness and in Health
- 1 December 2015
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 8 (12) , 1401-1403
In Sickness and in Health
- 1 November 2011
- Vol. 23 (11) , 465-6
Stent evaluation by coronary computed tomographic angiography and expert consensus documents.
- 1 November 2011
- Vol. 23 (11) , 465-6
Stent evaluation by coronary computed tomographic angiography and expert consensus documents.
- 3 September 2011
- Published by Springer Nature in Current Cardiology Reports
- Vol. 13 (6) , 465-474
Coronary Artery Calcium: Utilization for Primary Prevention of CHD
The rapidly accumulating data supporting coronary artery calcium (CAC) has necessitated multiple paradigm shifts in primary prevention: 1) CAC is the most powerful predictor of cardiac risk in the asymptomatic primary prevention population. 2) The most important role of risk factors may be to identify the modifiable targets of risk reduction in patients with risk already established by CAC. 3) “Normal cholesterol” values derived from population-based studies are not relevant for individual patients. 4) Measures of subclinical atherosclerosis (ie, serial CAC), rather than lipid values, define residual risk just as they define pretreatment risk. 5) Randomized controlled trials are not a prerequisite for implementation of CAC screening. 6) Trials evaluating lipid-treating drugs should exclude patients with 0 CAC. 7) CAC is the most cost-effective primary prevention approach.
- 3 September 2011
- Published by Springer Nature in Current Cardiology Reports
- Vol. 13 (6) , 465-474
Coronary Artery Calcium: Utilization for Primary Prevention of CHD
The rapidly accumulating data supporting coronary artery calcium (CAC) has necessitated multiple paradigm shifts in primary prevention: 1) CAC is the most powerful predictor of cardiac risk in the asymptomatic primary prevention population. 2) The most important role of risk factors may be to identify the modifiable targets of risk reduction in patients with risk already established by CAC. 3) “Normal cholesterol” values derived from population-based studies are not relevant for individual patients. 4) Measures of subclinical atherosclerosis (ie, serial CAC), rather than lipid values, define residual risk just as they define pretreatment risk. 5) Randomized controlled trials are not a prerequisite for implementation of CAC screening. 6) Trials evaluating lipid-treating drugs should exclude patients with 0 CAC. 7) CAC is the most cost-effective primary prevention approach.
- 1 August 2011
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 18 (4) , 695-699
Controversies in nuclear cardiology: CT calcium scoring should be routinely performed in patients undergoing myocardial perfusion imaging who have a normal test result (and should be routinely performed before myocardial perfusion imaging)—pro
- 1 August 2011
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 18 (4) , 695-699
Controversies in nuclear cardiology: CT calcium scoring should be routinely performed in patients undergoing myocardial perfusion imaging who have a normal test result (and should be routinely performed before myocardial perfusion imaging)—pro
- 27 July 2011
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 13 (5) , 422-430
The Role of Atherosclerosis Imaging in Redefining Normal and Abnormal Cholesterol Values, and Risk Reduction in Primary Prevention Statin Trials
The emergence of atherosclerosis imaging, using coronary calcium scanning (CAC) and carotid intima media thickness (CIMT) and plaque as stronger predictors of cardiovascular events than risk factors of atherosclerosis, has created a paradigm shift in the primary prevention of cardiovascular disease. Rather than population-derived indices to define normal or abnormal low-density lipoprotein (or other lipid values) in the untreated individual patient, it is more appropriate to define “normal” as “cholesterol values at which level there is no subclinical atherosclerosis” and “abnormal” as “cholesterol values at which level there is subclinical atherosclerosis,” with the severity of “abnormal” depending on the degree of subclinical atherosclerosis. Similarly, the low-density lipoprotein treatment goal is the level at which atherosclerosis progression is halted. Extension of the subclinical atherosclerosis risk–based paradigms to primary prevention trials dramatically changes the manner in which trials should be conducted in the future, as well as the results of trials already performed. For example, asymptomatic patients with a CAC score of 0 have an extraordinarily low event rate but have been included in primary prevention statin trials even though their risk without treatment is very small. Reanalysis of the statin primary prevention trials after excluding the percentage (40%) of patients who would be expected to have a CAC score of 0 yields an absolute risk increase of 60% in both the placebo group (from 5.4% to 8.5%), and the statin group (from 3.0% to 4.8%). Absolute risk reduction increased by 58% (from 2.4% to 3.8%). Relative risk reduction of 44% was unchanged. In conclusion, 1) the presence or absence of atherosclerosis as measured by CAC redefines normal or abnormal lipid levels in an individual patient; 2) statin absolute risk reduction is significantly greater than previously appreciated; and 3) patients with a CAC score of 0 should be excluded from primary prevention randomized controlled trials.
- 27 July 2011
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 13 (5) , 422-430
The Role of Atherosclerosis Imaging in Redefining Normal and Abnormal Cholesterol Values, and Risk Reduction in Primary Prevention Statin Trials
The emergence of atherosclerosis imaging, using coronary calcium scanning (CAC) and carotid intima media thickness (CIMT) and plaque as stronger predictors of cardiovascular events than risk factors of atherosclerosis, has created a paradigm shift in the primary prevention of cardiovascular disease. Rather than population-derived indices to define normal or abnormal low-density lipoprotein (or other lipid values) in the untreated individual patient, it is more appropriate to define “normal” as “cholesterol values at which level there is no subclinical atherosclerosis” and “abnormal” as “cholesterol values at which level there is subclinical atherosclerosis,” with the severity of “abnormal” depending on the degree of subclinical atherosclerosis. Similarly, the low-density lipoprotein treatment goal is the level at which atherosclerosis progression is halted. Extension of the subclinical atherosclerosis risk–based paradigms to primary prevention trials dramatically changes the manner in which trials should be conducted in the future, as well as the results of trials already performed. For example, asymptomatic patients with a CAC score of 0 have an extraordinarily low event rate but have been included in primary prevention statin trials even though their risk without treatment is very small. Reanalysis of the statin primary prevention trials after excluding the percentage (40%) of patients who would be expected to have a CAC score of 0 yields an absolute risk increase of 60% in both the placebo group (from 5.4% to 8.5%), and the statin group (from 3.0% to 4.8%). Absolute risk reduction increased by 58% (from 2.4% to 3.8%). Relative risk reduction of 44% was unchanged. In conclusion, 1) the presence or absence of atherosclerosis as measured by CAC redefines normal or abnormal lipid levels in an individual patient; 2) statin absolute risk reduction is significantly greater than previously appreciated; and 3) patients with a CAC score of 0 should be excluded from primary prevention randomized controlled trials.
- 21 July 2011
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 78 (5) , 755-763
Stent sizing by coronary computed tomographic angiography: Comparison with conventional coronary angiography in an experienced setting
The goal was to compare stent sizing by coronary computed tomographic angiography (CCTA) with that deployed in an experienced setting based upon conventional coronary angiography (CA). Stent sizing is currently performed by visual estimation, with infrequent guidance by intravascular ultrasound. CCTA permits quantitative determination of stent length (Stent L) and diameter (Stent D). Projected L (CTA-Stent L) and D (CTA-Stent D) were determined from CCTA obtained in 248 patients with 352 lesions undergoing percutaneous coronary intervention within 4 months of the CCTA, and were compared to the Stent-L and Stent-D of the actually deployed stents. The effects of lesion modification and calcified plaque were also evaluated. There were significant correlations between CTA-Stent L and Stent L (r = 0.656, P < 0.0001) and between CTA-Stent D and Stent D (r = 0.40, P < 0.001). Median predicted CTA-Stent L was slightly longer (20 mm vs. 18 mm, P < 0.0001) and predicted CTA-Stent D was slightly smaller (3.0 mm vs. 3.2 mm, P < 0.0001) than Stent-L and Stent-D, respectively. The differences were unchanged in stents with lesion modification by pre-dilation or intracoronary nitroglycerin. CTA Stent-L and CTA Stent-D increased significantly with increasing calcium (P < 0.0001 and P = 0.019, respectively). (1) There are significant correlations between CCTA and CA based stent sizing in an experienced setting. (2) CCTA projects slightly longer and slightly smaller diameter stents than those deployed during PCI irrespective of lesion modification; the small differences are unlikely to have clinical significance. (3) CCTA may offer a noninvasive alternative to intravascular ultrasound for stent planning.
- 21 July 2011
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 78 (5) , 755-763
Stent sizing by coronary computed tomographic angiography: Comparison with conventional coronary angiography in an experienced setting
The goal was to compare stent sizing by coronary computed tomographic angiography (CCTA) with that deployed in an experienced setting based upon conventional coronary angiography (CA). Stent sizing is currently performed by visual estimation, with infrequent guidance by intravascular ultrasound. CCTA permits quantitative determination of stent length (Stent L) and diameter (Stent D). Projected L (CTA-Stent L) and D (CTA-Stent D) were determined from CCTA obtained in 248 patients with 352 lesions undergoing percutaneous coronary intervention within 4 months of the CCTA, and were compared to the Stent-L and Stent-D of the actually deployed stents. The effects of lesion modification and calcified plaque were also evaluated. There were significant correlations between CTA-Stent L and Stent L (r = 0.656, P < 0.0001) and between CTA-Stent D and Stent D (r = 0.40, P < 0.001). Median predicted CTA-Stent L was slightly longer (20 mm vs. 18 mm, P < 0.0001) and predicted CTA-Stent D was slightly smaller (3.0 mm vs. 3.2 mm, P < 0.0001) than Stent-L and Stent-D, respectively. The differences were unchanged in stents with lesion modification by pre-dilation or intracoronary nitroglycerin. CTA Stent-L and CTA Stent-D increased significantly with increasing calcium (P < 0.0001 and P = 0.019, respectively). (1) There are significant correlations between CCTA and CA based stent sizing in an experienced setting. (2) CCTA projects slightly longer and slightly smaller diameter stents than those deployed during PCI irrespective of lesion modification; the small differences are unlikely to have clinical significance. (3) CCTA may offer a noninvasive alternative to intravascular ultrasound for stent planning.
- 8 November 2010
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 77 (6) , 843-859
Current and evolving stent evaluation by coronary computed tomographic angiography
Objectives: To demonstrate the variety of stent abnormalities that may be evaluated by coronary computed tomographic angiography (CTA). Background: The application of CTA to the evaluation of coronary stents has focused almost entirely on the detection of in-stent restenosis. Methods: All CTA performed for stent evaluation at a single institution were reviewed. Results: In addition to in-stent restenosis, stent fracture, and overlap failure, a multiplicity of stent-related problems not previously addressed by CTA was categorized and illustrated: late stent thrombosis, jailed branches, edge stenosis, bifurcation stents, inadequate stent expansion, stent aneurysms, peri-stent plaque, and stenting into bridged myocardium. Conclusions: CTA may be used to evaluate the full range of stent-related problems. This work provides the framework for future studies validating these applications.
- 8 November 2010
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 77 (6) , 843-859
Current and evolving stent evaluation by coronary computed tomographic angiography
Objectives: To demonstrate the variety of stent abnormalities that may be evaluated by coronary computed tomographic angiography (CTA). Background: The application of CTA to the evaluation of coronary stents has focused almost entirely on the detection of in-stent restenosis. Methods: All CTA performed for stent evaluation at a single institution were reviewed. Results: In addition to in-stent restenosis, stent fracture, and overlap failure, a multiplicity of stent-related problems not previously addressed by CTA was categorized and illustrated: late stent thrombosis, jailed branches, edge stenosis, bifurcation stents, inadequate stent expansion, stent aneurysms, peri-stent plaque, and stenting into bridged myocardium. Conclusions: CTA may be used to evaluate the full range of stent-related problems. This work provides the framework for future studies validating these applications.